Involvement of the inhibition of intestinal glucuronidation in enhancing the oral bioavailability of resveratrol by labrasol containing nanoemulsions.
Nanoemulsions have been developed for the oral delivery of poorly bioavailable phenolic compounds that are sensitive to intestinal glucuronidation. However, little is known about the contribution of UDP-glucuronosyltransferase (UGT) inhibitory excipients in nanoemulsions toward the inhibition of intestinal glucuronidation and the consequent enhanced bioavailability. In this study, Labrasol but not poloxamer 188 (F68) was found to inhibit the glucuronidation of resveratrol (RES), a model phenolic compound, in an inhibition assay with rat microsomes. Subsequently, two nanoemulsions, Lab-N and F68-N, were prepared with similar particle size distribution, zeta potentials, and entrapment efficiency by coemulsifying with Labrasol or F68, respectively. Although Lab-N exhibited inferior or comparable profiles of in vitro release, cellular uptake in Caco-2 cells, and lymphatic transport in rats to F68-N, the in vitro absorption study with everted sacs suggested that Labrasol containing formulations significantly and dose-dependently increased the transport of RES relative to free RES or F68-N by decreasing the amount of permeated metabolite, RES-3-glucuronide (RES-G). The in vivo pharmacokinetic experiments indicated that Lab-N exhibited increments in the maximum plasma concentration and the bioavailability of RES by 1098% and 560%, respectively, and significant decreases in those of RES-G, compared to F68-N. The overall results demonstrated that the improved oral bioavailability of RES by Lab-N was mainly attributable to the inhibition of intestinal glucuronidation by the presence of UGT inhibitory excipient.
Jing
J
Zhou
Man
M
Zhou
Fei-Fei
FF
Yang
Chun-Yu
CY
Liu
Rui-Le
RL
Pan
Qi
Q
Chang
Xin-Min
XM
Liu
Yong-Hong
YH
Liao
D000284:Administration, Oral; D000818:Animals; D019540:Area Under Curve; D001682:Biological Availability; D018938:Caco-2 Cells; D004655:Emulsions; D014453:Glucuronosyltransferase / Q000737:chemistry*; D005989:Glycerides / Q000737:chemistry*; D006801:Humans; D007413:Intestinal Mucosa / Q000378:metabolism; D007421:Intestine, Small / Q000187:drug effects; D007422:Intestines / Q000187:drug effects*; D008297:Male; D008861:Microsomes / Q000378:metabolism; D008862:Microsomes, Liver / Q000187:drug effects / Q000378:metabolism; D053758:Nanoparticles / Q000737:chemistry; D010316:Particle Size; D019800:Phenol / Q000737:chemistry; D051381:Rats; D017208:Rats, Wistar; D000077185:Resveratrol; D013267:Stilbenes / Q000737:chemistry*; D014530:Uridine Diphosphate / Q000737:chemistry
D004655:Emulsions; D005989:Glycerides; D013267:Stilbenes; C440220:Labrasol; D019800:Phenol; D014530:Uridine Diphosphate; D014453:Glucuronosyltransferase; D000077185:Resveratrol
UDP-glucuronosyltransferases (UGT); glucuronidation; nanoemulsion; oral bioavailability; resveratrol